Healthscope (HSP.AU) could be takeover/break up target, says
Australian Financial Review. Reports Symbion Health (SYB.AU) board meeting last week
believed to have considered picking up some of HSP's pathology assets. Ironbridge
Capital and CVC Asia Pacific seen leading charge for break up. Some institutional dealers
were last week pushing this line of likely takeover or substantial interest from SYB in
HSP. Other dealers don't think it's likely. But AFR report should be enough to
see continued outperformance from HSP shares today after Friday's bounce from
11-month low of A$3.84 to A$4.17. (DWR)
Add to My Watchlist
What is My Watchlist?